<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04063683</url>
  </required_header>
  <id_info>
    <org_study_id>2019315</org_study_id>
    <nct_id>NCT04063683</nct_id>
  </id_info>
  <brief_title>Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.</brief_title>
  <official_title>Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma: a Single Arm, Multicentre Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of paclitaxel and DDP combined with Anlotinib in the&#xD;
      treatment of advanced esophageal squamous cell carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 7, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress free survival (PFS)</measure>
    <time_frame>From first treatment，each 42 or 63 days until PD or death(up to 24 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>each 42 or 63 days until intolerant the toxicity or PD (up to 24 months) ]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>each 42 or 63 days until intolerant the toxicity or PD (up to 24 months) ]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response(DOR)</measure>
    <time_frame>each 42 or 63 days until intolerant the toxicity or PD (up to 24 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Anlotinib with chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib Hydrochloride, Paclitaxel, cisplatin</intervention_name>
    <description>anlotinib: 1 capsule (10mg) once a day, d1-d14 per cycle, 3 weeks for a treatment cycle.&#xD;
Paclitaxel: intravenously infused at 135mg/ m2, administered d1 per cycle, 3 weeks for a treatment cycle.&#xD;
Cisplatin: administered after paclitaxel, intravenously infused at 60-75 mg/m2, divided into d1-d3 medications per cycle; 3 weeks for one treatment cycle.</description>
    <arm_group_label>Anlotinib with chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histopathology confirmed unresectable, locally recurrent or metastatic advanced&#xD;
             esophageal squamous cell carcinoma (excluding mixed type adenosquamous carcinoma );&#xD;
&#xD;
          -  Those who have not received systemic treatment before, or who relapsed after (new)&#xD;
             adjuvant therapy/radical surgery more than 6 months ; Note: Including advanced or&#xD;
             recurrent Patients who ever received only radiotherapy on non-target lesions. The&#xD;
             duration from the end of palliative treatment for local lesions (non-target lesions)&#xD;
             to enrollment should &gt; 2 weeks;&#xD;
&#xD;
          -  According to RECIST 1.1, at least one measurable lesion; the measurable lesions should&#xD;
             not have received local treatment such as radiotherapy (for the lesions in the area&#xD;
             where received local radiotherapy, it can also be regarded as a target lesion if&#xD;
             confirmed to progress according to the recist1.1);&#xD;
&#xD;
          -  Age from 18-75 years old;&#xD;
&#xD;
          -  ECOG PS score: 0-1; expected survival time more than 3 months;&#xD;
&#xD;
          -  Main organs function is normal;&#xD;
&#xD;
          -  Women of childbearing potential should agree to use and utilize an adequate method of&#xD;
             contraception (such as intrauterine device，contraceptive and condom) throughout&#xD;
             treatment and for at least 3 months after study is stopped；the result of serum or&#xD;
             urine pregnancy test should be negative before enrollment；Man participants should&#xD;
             agree to use and utilize an adequate method of contraception throughout treatment and&#xD;
             for at least 2 months after study is stopped.&#xD;
&#xD;
          -  Patients should participate in the study voluntarily and sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients tends to have complete obstruction or patients requiring interventional&#xD;
             treatment for obstruction;&#xD;
&#xD;
          -  ulcerated esophageal squamous cell carcinoma patients;&#xD;
&#xD;
          -  after esophageal or endotracheal stent implantation;&#xD;
&#xD;
          -  Patients with a high risk of bleeding or perforation due to the apparent invasion of&#xD;
             adjacent organs (aorta or trachea) of the esophageal lesion, or patients who have&#xD;
             formed fistulas;&#xD;
&#xD;
          -  patients with ESCC who have not undergone surgical resection but have not reduced&#xD;
             esophageal lesions after radiotherapy;&#xD;
&#xD;
          -  allergic to paclitaxel and cisplatin preparations or excipients;&#xD;
&#xD;
          -  Adjuvant chemotherapy patients who have used paclitaxel or cisplatin, and relapse or&#xD;
             metastasize within one year;&#xD;
&#xD;
          -  A variety of factors affecting oral medications (such as inability to swallow, chronic&#xD;
             diarrhea, and intestinal obstruction);&#xD;
&#xD;
          -  The of liver metastases accounts for more than 50% of the total liver volume;&#xD;
&#xD;
          -  patients with any severe and / or uncontrolled disease, including:Unsatisfactory blood&#xD;
             pressure control using antihypertensive drugs (systolic blood pressure ≥150 mmhg or&#xD;
             diastolic blood pressure ≥100) Mmhg) patients; patients with grade ≥ myocardial&#xD;
             ischemia or myocardial infarction, arrhythmia (including qt interval ≥ 480ms);&#xD;
             according to nyha criteria, iii-iv cardiac dysfunction, or cardiac ultrasonography&#xD;
             prompted left ventricular ejection fraction (lvef) &lt;50% of patients;live Severe&#xD;
             infection that is sexual or uncontrolled;Liver diseases such as cirrhosis,&#xD;
             decompensated liver disease, chronic active hepatitis;poor diabetes control (fasting&#xD;
             blood glucose (fbg)&gt;10mmol/l);Urine routine indicates that urine protein ≥ ++, and&#xD;
             confirmed 24-hour urine protein quantitation &gt; 1.0 g;&#xD;
&#xD;
          -  long-term unhealed wounds or fractures;&#xD;
&#xD;
          -  Patients with active hemorrhage within 2 months of primary lesions; pulmonary&#xD;
             hemorrhage with NCI CTC AE grade &gt;1, 4 weeks before of enrollment; other sites of&#xD;
             bleeding NCI CTC AE grade &gt;2, 4 weeks before of enrollment; patients with bleeding&#xD;
             tendency (such as active gastrointestinal ulcers) or patients undergoing thrombolytic&#xD;
             or anticoagulant therapy such as warfarin, heparin or its analogues;&#xD;
&#xD;
          -  Have undergone major surgery (craniotomy, thoracotomy or open surgery) within 4 weeks&#xD;
             prior to the first dose study or Major surgery is required during the study period.&#xD;
&#xD;
          -  A history of gastrointestinal perforation and/or fistula occurred within 6 months&#xD;
             prior to treatment; or an overactive/venous thrombosis event such as a cerebrovascular&#xD;
             accident (including transient ischemic attack), deep vein thrombosis, and lung&#xD;
             Embolism.&#xD;
&#xD;
          -  Symptomatic central nervous system metastasis and/or cancerous meningitis are known to&#xD;
             exist;&#xD;
&#xD;
          -  Clinically significant ascites, including any ascites that can be found on a physical&#xD;
             examination, ascites that has been treated or currently in need of treatment, and only&#xD;
             those with a small amount of ascites but no symptoms can be selected;&#xD;
&#xD;
          -  A moderate amount of fluid in both sides of the chest, or a large amount of fluid in&#xD;
             one side of the chest, or has caused respiratory dysfunction Patient to be drained;&#xD;
&#xD;
          -  known to have active tuberculosis;&#xD;
&#xD;
          -  suffering from interstitial lung disease requiring steroid therapy;&#xD;
&#xD;
          -  Uncontrolled metabolic disorders or other non-malignant tumors or systemic diseases or&#xD;
             cancer secondary reactions that can lead to higher medical risks and/or survival&#xD;
             Evaluation of uncertainty;&#xD;
&#xD;
          -  Significantly malnourished patients;&#xD;
&#xD;
          -  those who have a history of psychotropic substance abuse and are unable to quit or&#xD;
             have a mental disorder;&#xD;
&#xD;
          -  A history of immunodeficiency, including a positive HIV test or other acquired,&#xD;
             congenital immunodeficiency disease, or a history of organ transplantation;&#xD;
&#xD;
          -  History of other primary malignancies, but the following : 1) complete remission of&#xD;
             malignant tumors for at least 2 years prior to enrollment and no additional treatment&#xD;
             during the study; 2) non-melanoma skin cancer or malignant freckle-like sputum with&#xD;
             adequate treatment and no evidence of disease recurrence; 3) adequately treated and In&#xD;
             situ carcinoma without evidence of disease recurrence;&#xD;
&#xD;
          -  Female patients who are pregnant or breastfeeding&#xD;
&#xD;
          -  According to the investigator's judgment, there are serious concomitant diseases that&#xD;
             endanger the safety of the patient or affect the patient's completion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LUO SUXIA</last_name>
    <role>Study Chair</role>
    <affiliation>Henan Cancer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ANYANG Cancer Hospital</name>
      <address>
        <city>Anyang</city>
        <state>Henan</state>
        <zip>455000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Henan University of Science and Technolog</name>
      <address>
        <city>Luoyan</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan cancer hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shandong Cancer Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linyi Central Hospital</name>
      <address>
        <city>Linyi</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 19, 2019</study_first_submitted>
  <study_first_submitted_qc>August 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2019</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

